Medpace Holdings (MEDP)
NASDAQ:MEDP
Want to see MEDP full AI Analyst Report?
Earnings Data
Report Date
Jul 27, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
3.98Last Year’s EPS
3.1Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call showed strong underlying financial performance in Q1 — double-digit revenue and EBITDA growth, healthy cash generation, and a sizable backlog — and management reaffirmed full-year guidance. However, elevated and persistent cancellations, weaker gross bookings/RFPs and a multi-quarter decline in beyond-12-month backlog coverage are meaningful near- to medium-term risks to sequential growth. Management pointed to a good win rate and initiatives to improve pipeline conversion, but the cadence and durability of that improvement remain uncertain.Company Guidance
Strong Revenue Growth
Q1 2026 revenue of $706.6 million, up 26.5% year-over-year (25.8% constant currency).
Robust EBITDA Expansion
EBITDA of $149.4 million, up 25.9% year-over-year (28.6% on a constant currency basis); EBITDA margin broadly stable at 21.1% vs 21.2% prior year.
Healthy Net Bookings vs Prior Year
Net new business awards entering backlog of $618.4 million, up 23.7% year-over-year, demonstrating continued demand (net book-to-bill 0.88 due to higher cancellations and timing).
Large Backlog with Near-Term Convertibility
Ending backlog approximately $2.9 billion (+2.9% year-over-year) with ~$1.94 billion projected to convert to revenue in the next 12 months; Q1 backlog conversion was 23.3% of beginning backlog.
Strong Cash Generation and Liquidity
Generated $151.8 million of cash flow from operating activities in Q1 and ended the quarter with $652.7 million in cash; net days sales outstanding was negative 58.8 days.
Solid Per-Share and Net Income Performance
Net income of $123.9 million (+8.1% YoY) and diluted EPS of $4.28 vs $3.67 in prior year.
Reaffirmed Full-Year Guidance and Capital Flexibility
2026 guidance for revenue, EBITDA, net income and EPS unchanged; management also noted existing share repurchase authorization (just over $800M) and will continue execution, though no repurchases are included in guidance.
Win Rate and Opportunity Quality Called Out as Strong
Management highlighted strong initial award notifications and win rate and described the quality of opportunity flow as 'good,' and confirmed active initiatives to improve win rate.
MEDP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MEDP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 22, 2026 | $508.46 | $393.42 | -22.63% |
Feb 09, 2026 | $530.35 | $446.05 | -15.90% |
Oct 22, 2025 | $546.74 | $596.61 | +9.12% |
Jul 21, 2025 | $308.88 | $477.73 | +54.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Medpace Holdings (MEDP) report earnings?
Medpace Holdings (MEDP) is schdueled to report earning on Jul 27, 2026, After Close (Confirmed).
What is Medpace Holdings (MEDP) earnings time?
Medpace Holdings (MEDP) earnings time is at Jul 27, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MEDP EPS forecast?
MEDP EPS forecast for the fiscal quarter 2026 (Q2) is 3.98.